Abstract
Background There is controversy about the benefit of administering adjuvant therapy to esophageal cancer (EC) patients after preoperative neoadjuvant therapy and surgical treatment. This study aims to investigate the impact of postoperative adjuvant therapy in EC patients with neoadjuvant therapy and surgery.
Materials and methods The study included EC patients diagnosed from 2007 to 2020 in the Surveillance, Epidemiology, and End Results (SEER) database. Patients who received neoadjuvant therapy (NCRT) were defined as those who underwent neoadjuvant chemotherapy or neoadjuvant radiotherapy before surgery, while patients who received adjuvant therapy (ACRT) were defined as those who underwent adjuvant chemotherapy or adjuvant radiotherapy after surgery. Propensity score matching (PSM) method was employed to establish matched cohorts, and Kaplan-Meier analysis, COX regression model, and Fine-Gray model were used for survival analysis.
Results The study included a total of 5805 EC patients, with 837 (14.4%) in the ACRT group and 4968 (85.4%) in the no-ACRT group. After PSM, a cohort of 1660 patients who received NCRT was enrolled for analysis, with 830 patients in each group. Kaplan-Meier analysis revealed no significant differences between the two groups in terms of median overall survival (OS) (34.0 vs. 36.0 months, P = 0.89) or cancer-specific survival (CSS) (40.0 vs. 49.0 months, P = 0.16). Multivariate Cox models and Fine-Gray models indicated that ACRT was not a predictive factor for OS or CSS (P > 0.05). Subgroup analysis for CSS suggested a protective effect of ACRT in the N2 (Cox model: HR = 0.640, P = 0.090; Fine-Gray model: HR = 0.636, P = 0.081) and the N3 subgroup (Cox model: HR = 0.302, P = 0.018; Fine-Gray model: HR = 0.306, P = 0.034).
Conclusions Only for esophageal cancer patients with a more advanced N stage, postoperative adjuvant therapy after completing neoadjuvant therapy and curative surgical treatment may be beneficial.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As per the determination of our institutional ethics committee, this study is not considered human subjects research and does not require approval from an institutional review board, as it utilizes previously identified data from secondary research sources.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
All the data used in this study were publicly available in the SEER database (https://seer.cancer.gov/).
Abbreviations
- ACRT
- adjuvant radiotherapy or adjuvant chemotherapy
- ADC
- adenocarcinoma
- CI
- confidence interval
- CSS
- confidence interval
- DFS
- disease-free survival
- EC
- esophageal cancer
- FGM
- Fine-Gray model
- HR
- hazard ratio
- NCRT
- neoadjuvant radiotherapy or neoadjuvant chemotherapy
- OCM
- other cause mortality
- OS
- overall survival
- PSM
- propensity score matching
- SCC
- squamous cell carcinoma
- SEER
- Surveillance, Epidemiology, and End Results.
